Researchers assessed the features of Parkinson disease (PD) pathophysiology that may increase the risk for COVID-19 mortality among hospitalized patients with PD.
Researchers analyzed brain MRI characteristics of patients with Huntington disease and related them to the major manifesting symptoms at clinical onset.
Researchers shared their findings on the cerebrospinal fluid profile of patients with fragile X-associated tremor/ataxia syndrome and potential biomarkers.
In a poster presented at MDS 2021 and as part 2 of the MOVES-PD trial, researchers assessed the safety and efficacy of venglustat, a glucosylceramide synthase inhibitor, in patients stratified by GBA gene variation severity.
At an abstract presented at MDS 2021, researchers described and analyzed eye movements in patients with an inborn errors of metabolism and their presence in early disease.
Researchers assessed the impact of specialized light therapy on motor and nonmotor symptoms in patients with Parkinson disease.
In a study presented at MDS 2021, researchers assessed the long-term safety and activity of ecopipam, a selective D1 antagonist, in reducing tics in children with Tourette syndrome.
Researchers observed the differences in gut microbiota composition between drug-naive and medically treated patients with Parkinson disease.
Researchers assessed predictors of persistence and discontinuation of deutetrabenazine in patients with Huntington disease and tardive dyskinesia.
In a poster presented at MDS 2021, researchers reported on the effect of early levodopa exposure on the onset of motor complications in patients with Parkinson disease.